NMTC (NeuroOne Medical Technologies) Research & Development: $5.16 Mil (TTM As of Mar. 2026)


NMTC NeuroOne Medical Technologies Corp NMTC
43 GF Score
Price $3.25
GF Value $6.58
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies Research & Development?

NeuroOne Medical Technologies NMTC -4.04% 43 Research & Development is $5.16 Mil as of Mar. 2026. GuruFocus rates NMTC with a GF Score™ of 43/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NeuroOne Medical Technologies's Research & Development for the three months ended in Mar. 2026 was $1.47 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $5.16 Mil.

NeuroOne Medical Technologies  (NAS:NMTC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NeuroOne Medical Technologies Research & Development Related Terms

NeuroOne Medical Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies Research & Development Chart

NeuroOne Medical Technologies Annual Data
Trend Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.93 4.93 6.94 5.07 4.98

NeuroOne Medical Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.18 1.12 1.39 1.47
NMTC
43GF Score
NeuroOne Medical Technologies Corp NMTC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroOne Medical Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.16 Mil mean?
NeuroOne Medical Technologies (NMTC) has a Research & Development of $5.16 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on NeuroOne Medical Technologies and its competitors.
Is NeuroOne Medical Technologies' Research & Development too high?
NeuroOne Medical Technologies' current Research & Development is $5.16 Mil. Overall, NeuroOne Medical Technologies has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Research & Development compare to CTSO and CODX?
NeuroOne Medical Technologies' Research & Development of $5.16 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current Research & Development is $5.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.25 — trading 50.6% below its estimated fair value. The current Research & Development is $5.16 Mil. NeuroOne Medical Technologies' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Research & Development is $5.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.25 is trading 50.6% below its estimated GF Value™ of $6.58. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

  • Research & Development: $5.16 Mil
  • GF Value™: $6.58 vs. price of $3.25 (50.6% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
43GF Score

Get the complete analysis for NMTC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price
$6.58
GF Value